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Single ingestion of soy 
β-conglycinin induces increased 
postprandial circulating FGF21 
levels exerting beneficial health 
effects
Tsutomu Hashidume1,2, Asuka Kato1, Tomohiro Tanaka1, Shoko Miyoshi1, Nobuyuki Itoh3, 
Rieko Nakata4, Hiroyasu Inoue4, Akira Oikawa5, Yuji Nakai6, Makoto Shimizu1, Jun Inoue1 & 
Ryuichiro Sato1
Soy protein β-conglycinin has serum lipid-lowering and anti-obesity effects. We showed that single 
ingestion of β-conglycinin after fasting alters gene expression in mouse liver. A sharp increase in 
fibroblast growth factor 21 (FGF21) gene expression, which is depressed by normal feeding, resulted 
in increased postprandial circulating FGF21 levels along with a significant decrease in adipose 
tissue weights. Most increases in gene expressions, including FGF21, were targets for the activating 
transcription factor 4 (ATF4), but not for peroxisome proliferator-activated receptor α. Overexpression 
of a dominant-negative form of ATF4 significantly reduced β-conglycinin-induced increases in hepatic 
FGF21 gene expression. In FGF21-deficient mice, β-conglycinin effects were partially abolished. 
Methionine supplementation to the diet or primary hepatocyte culture medium demonstrated its 
importance for activating liver or hepatocyte ATF4-FGF21 signaling. Thus, dietary β-conglycinin intake 
can impact hepatic and systemic metabolism by increasing the postprandial circulating FGF21 levels.
Obesity increases susceptibility to insulin resistance that can lead to metabolic syndrome. Under obesity con-
ditions, excess energy is stored as triglycerides in the liver as well as in adipose tissues, which worsens insulin 
sensitivity and causes hyperlipidemia. Soy protein, unlike animal proteins, is known to have beneficial effects 
by preventing body weight gain and improving blood lipid profiles1. The US Food and Drug Administration 
(FDA) authorized the health claim that daily ingestion of 25 g soy protein reduces the risk of cardiovascular heart 
disease2. Studies on the favorable effects of soy products have indicated that the effects are mostly exerted by the 
protein itself although isoflavones contained in an isolated soy protein fraction might make a minimal contribu-
tion to these effects3.
Soybeans contain abundant storage proteins and are highly valued as a nutritionally balanced dietary pro-
tein source. Soy protein is not a single protein but is composed of several types of proteins with different char-
acteristics. Among these proteins, β -conglycinin, comprising approximately 20% of the total soy protein, has 
been studied with the idea that it might explain most of soy’s beneficial effects. A number of animal and human 
studies showed that β -conglycinin, when compared with milk protein (casein), has anti-atherosclerotic, serum 
triglyceride-reducing, cholesterol-lowering, and anti-obesity effects4–6. Therefore, the focus of this study was to 
characterize these favorable physiological responses produced by dietary β -conglycinin. It should be noted that 
dietary soy protein appears to alter gene expression in adipose tissue and in particular may have induced an 
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Figure 1. Hepatic gene expression following β-conglycinin consumption for 6 h after 24 h fasting. Five-week 
old male mice were acclimated to the casein high-fat diet for 3 days. After 24 h fasting, mice were fed with either 
the casein or β -conglycinin (β -con) high-fat diet for 6 h as shown in Supplementary Table 3. Using liver total RNA, 
microarray analysis was performed according to the manufacturer’s instructions (n = 4). (a) GO terms associated 
with the genes that were up-regulated in the β -conglycinin group. FDR-corrected P values were defined by the 
modified Fisher’s exact test with the Benjamini and Hochberg FDR correction. FDR-corrected P values < 0.05 
are shaded in gray. (b) GO terms associated with the genes that were down-regulated in the β -conglycinin group. 
(c) Heatmap shows top twenty genes up-regulated or down-regulated by β -conglycinin ingestion from DNA 
microarray experiments. Green color indicates upregulation and red indicates downregulation in response to 
ingestion of two types of diet. (d) RT-qPCR was performed using total RNA used in DNA microarray experiments 
(n = 5). Relative expression levels of FGF21 and ATF4 mRNA in the liver are normalized to cyclophilin mRNA 
levels and are shown as fold induction to expression levels in the casein group. Serum FGF21 concentrations 
are determined by ELISA. All data are expressed as means ± SD (n = 5). * * P < 0.01 determined by two-tailed 
Student’s t-test.
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increase in expression of the adiponectin gene (Adipoq) expression and circulating adiponectin levels7. Although 
increased circulating Adipoq may partially explain physiological responses driven by dietary β -conglycinin or soy 
protein, the molecular mechanism for increasing Adipoq expression remains unknown8.
Here we show that gene expression in mouse liver is altered following β -conglycinin consumption, accompa-
nied by a decrease in blood glucose and insulin levels. The most significant increases were in fibroblast growth 
factor 21 gene (FGF21) expression in the liver and circulating FGF21 levels, which resulted in reduced body 
weight gain in response to a high-fat diet (HFD) intake. More surprisingly, a single ingestion of β -conglycinin 
after overnight fasting, rather than long-term feeding, was enough to induce an increase in hepatic FGF21 gene 
expression and circulating postprandial FGF21 levels. A number of reports have demonstrated that dietary condi-
tions such as fasting, protein restriction, and amino acid deprivation induce increased hepatic FGF21 expression 
as observed in hepatocytes cultured with the amino acid deprivation media9–16. In this study, we first report that a 
rapid activation of activating transcription factor 4 (ATF4) following consumption of a β -conglycinin-containing 
diet (not a low-protein or amino acid-deficient diet) triggers a significant increase in FGF21 expression in the 
liver, with a concurrent increase in lipolytic gene expression in epididymal white adipose tissue. We propose that 
a certain type of dietary protein have the ability to induce postprandial increases in serum FGF21 levels and exert 
beneficial health effects.
Results
Single ingestion of β-conglycinin after fasting causes a significant increase in hepatic FGF21 
expression. Previously published papers and our preliminary experiments showed that long-term consump-
tion of β -conglycinin as a dietary protein source resulted in an improvement in lipid metabolism and prevented 
body weight gain in mice5,8,17. These findings raised the hypothesis that slight changes in gene expression, par-
ticularly in the liver, initiated by a single ingestion of β -conglycinin, rather than long-term consumption, appear 
to have occurred. To address this issue, we attempted to find rapid changes in gene expression using intensive 
DNA microarray analyses with hepatic RNA prepared from mice fasted for 24 h and then fed either a β -congly-
cinin- or casein-containing HFD for 6 h. To identify gene ontology (GO) terms that were overrepresented among 
the differentially expressed genes, we first performed a gene-annotation enrichment analysis using the online 
software program the Database for Annotation, Visualization, and Integrated Discovery (DAVID). The GO terms 
were significantly enriched in the genes that were up-regulated after β -conglycinin treatment are summarized in 
Fig. 1a. The hierarchical structure of GO that facilitated the identification of more specific GO terms appeared 
more imbedded in the hierarchy. The GO terms enriched in the genes up-regulated by the β -conglycinin treat-
ment were glucose metabolic, carboxylic acid biosynthetic, oxidation-reduction process, cholesterol/isoprenoid 
biosynthetic, fatty acid metabolic, carboxylic acid catabolic, generation of precursor metabolites and energy, and 
coenzyme/sulfur-compound metabolic process. The GO term significantly enriched in the genes down-regu-
lated after β -conglycinin treatment was mRNA processing (Fig. 1b). These results clearly show that β -conglycinin 
ingestion rapidly altered the mRNA levels of genes involved in some metabolic processes that are known to be 
affected by β -conglycinin long-term feeding. Surprisingly, the heat map listing the genes significantly changed 
by β -conglycinin showed FGF21 was the most highly up-regulated gene, followed by Igfbp-1 and Psat1 (Fig. 1c). 
Indeed, circulating FGF21 levels were significantly increased 6 h after ingestion of the β -conglycinin diet, in con-
junction with a significant increase in its mRNA levels as determined by the real-time PCR (qPCR) method 
(Fig. 1d). Another distinguishing feature of the results shown in the heat map was that most of the up-regu-
lated genes were targets of the transcription factor, ATF4; these genes included Psat1, Chac1, Gadd45a, Trib3, 
Snat2, and Asns (Fig. 1c). Interestingly, ATF4 gene expression was also increased by β -conglycinin consumption 
(Fig. 1d). Although ATF4 is known to become activated in response to endoplasmic reticulum (ER) stress, the 
current DNA microarray results showed no increase in the expression of ER stress genes, such as Xbp1 and 
Bip, indicating that no ER stress occurred after β -conglycinin consumption. Although the hepcidin gene (Hamp) 
involved in systemic iron homeostasis was the most highly down-regulated gene by β -conglycinin (Fig. 1c), we 
found in pilot experiments that ATF4 was not a direct regulator for Hamp gene expression; the precise mecha-
nism, however, for its reduced expression remains unclear. Another gene down-regulated by β -conglycinin was 
Insig1. A decrease in this protein would theoretically result in the activation of sterol regulatory element-binding 
proteins, thereby leading to an increase in the synthesis of cholesterol and fatty acids. This assumption contradicts 
the favorable effects of β -conglycinin on lipid metabolism improvements; this has been confirmed in a couple of 
animal experiments by long-term β -conglycinin feeding5,8,17, and it seems unlikely that a decrease in Insig1 would 
be physiologically relevant in vivo.
FGF21 contributes to a large portion of the effects of β-conglycinin. FGF21 is believed to be a 
humoral signal that increases insulin sensitivity and energy expenditure, thereby exerting multiple metabolic 
effects. Because DNA microarray analyses revealed a rapid increase in hepatic FGF21 expression and cir-
culating FGF21 levels following β -conglycinin ingestion, we aimed to determine whether increased circulat-
ing FGF21 levels remain elevated after a long-term β -conglycinin consumption, not just post- ingestion, and 
whether β -conglycinin still serves as a functional dietary protein in FGF21-deficient mice. Wild-type (WT) 
and FGF21-deficient mice were fed either a casein- or β -conglycinin-containing HFD for 9 weeks. Although 
β -conglycinin slightly prevented body weight gain even in FGF21-deficient mice, its anti-obesity effect was 
prominent in WT mice despite the fact that daily intake of the β -conglycinin diet was slightly but rather signifi-
cantly higher, suggesting that FGF21 largely contributed to preventing body weight gain (Fig. 2a–c). Moreover, 
β -conglycinin significantly reduced adipose tissue weights (epididymal, subcutaneous white adipose tissue 
(WAT), and brown adipose tissue (BAT)), whereas no changes were observed in FGF21-deficient mice (Fig. 2d). 
Even though much time had passed after meal ingestion and the mice were fasted for 6 h, hepatic FGF21 gene 
expression and serum FGF21 levels were significantly increased after the 9-week β -conglycinin feeding in WT 
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Figure 2. Beneficial effects of β-conglycinin in wild-type (WT) or FGF21-deficient (KO) mice. Five-week-
old male WT and FGF21 KO mice were acclimated to the casein high-fat diet for 7 days, and then fed with 
either the casein or β -conglycinin (β -con) diet for 9 weeks. After 6 h of starvation, mice were sacrificed.  
(a) Body weight of mice. All data are expressed as means ± SD (n = 6–8). (b) Total food consumption over 9 
weeks. * * P < 0.01 determined by two-tailed Student’s t-test. (c) Body weight gain over 9 weeks. (d) Adipose 
tissue (epididymal and subcutaneous white adipose tissue, and brown adipose tissue) weights of mice.  
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mice (Fig. 2e,f), suggesting that increased circulating FGF21 might contribute to adipose tissue weight loss. 
Serum glucose levels were lowered by β -conglycinin in both types of mice, whereas serum insulin and total cho-
lesterol levels were reduced only in WT mice (Fig. 2g,h,j). There was no significant change in serum triglyceride 
levels (Fig. 2i). Interestingly, serum levels of Igf-1, one of FGF21 target genes18, were decreased by β -conglycinin 
consumption in both types of mice, suggesting that the attenuation of body weight gain by β -conglycinin might 
be partly caused by this decrease (Fig. 2k). Liver triglyceride levels were lowered by β -conglycinin treatment 
more significantly in WT mice than those in the FGF21-KO mice (Fig. 2l). Liver total cholesterol levels under-
went similar changes in serum levels in both types of mice (Fig. 2m). Hepatic gene expressions of other ATF4 
targets, including Asns and Psat1 that are involved in amino acid metabolism, were substantially increased by 
β -conglycinin in both WT and FGF21-deficient mice, suggesting that ATF4 served as the primary regulatory fac-
tor over FGF21 (Fig. 2n). Consistent with previously published data5, β -conglycinin decreased the mRNA levels 
of Fas and Scd1 in both types of mice, indicating that β -conglycinin effectively prevented fatty liver induced by 
HFD independently of FGF21 functions (Fig. 2o). Meanwhile, there were no significant changes in PPARγ 2 and 
Srebp-1c gene expressions induced by only β -conglycinin in FGF21-deficient mice; this was consistent with the 
finding that some serum profiles, including insulin, total cholesterol, and triglyceride concentrations, were not 
fully lowered by β -conglycinin consumption in these mice. When gene expressions in the ileum were analyzed, 
we found that β -conglycinin caused a decrease in gene expressions of Fxr targets, including FGF15 and Ibabp, in 
both types of mice (Fig. 2p). These results suggest that β -conglycinin improved lipid metabolism through lowered 
bile acid absorption independently of FGF21.
A primary target of FGF21 is proposed to be adipose tissues, where it induces increased expression of a subset 
of genes related to energy expenditure. To address its action in adipose tissues in response to β -conglycinin con-
sumption, we investigated the effect of the β -conglycinin diet on metabolic gene expression in epididymal, subcu-
taneous WAT, and BAT. In epididymal WAT, β -conglycinin consumption resulted in a significant increase in the 
expression of Atgl, Hsl, Adipoq, and Pgc-1α genes that have been reported to be up-regulated by FGF21 in several 
papers19–22. This increment was slightly observed in FGF21-deficient mice (Fig. 2q). The expression of Adipoq, 
Ucp-1 (in subcutaneous WAT) and Atgl (in BAT) was increased by β -conglycinin consumption (Fig. 2r,s). These 
results imply that the increased secretion of FGF21 from the liver in response to β -conglycinin intake caused loss 
of adipose tissue weights, accompanied by increased metabolic gene expression in WAT and BAT.
Increased FGF21 gene expression in response to β-conglycinin ingestion is not caused by 
PPARα. FGF21 expression is induced in the murine liver in response to fasting18,19. PPARα is believed 
to be a primary hepatic regulator of FGF21 expression. Following food intake, the expression is likely to be 
reduced in conjunction with inactivation of PPARα . To investigate the effect of PPARα on increased FGF21 
expression by β -conglycinin consumption, WT and PPARα -deficient mice were fed either the casein- or 
β -conglycinin-containing diet for 4 weeks. We found that both hepatic FGF21 expression and serum FGF21 levels 
became elevated even in PPARα -deficient mice (Fig. 3a). These results clearly show that there was no association 
between β -conglycinin ingestion and PPARα activation. The body, liver, and epididymal WAT weights were all 
reduced by β -conglycinin consumption in both types of mice (Fig. 3b–d). The β -conglycinin diet lowered serum 
glucose, TG, and total-cholesterol levels independently of PPARα (Fig. 3e–g). Taken together, we concluded that 
the favorable effects of β -conglycinin were not caused by activation of PPARα .
ATF4 is involved in induction of increased FGF21 gene expression after β-conglycinin ingestion. 
We next investigated the effect of ATF4 on the FGF21’s promoter activity. Reporter gene analyses, using a lucif-
erase construct with the 1.1-kb promoter region of the mouse FGF21 gene, revealed that overexpression of mouse 
ATF4 enhanced its transcription through the upstream amino acid response element (AARE) 1 (Fig. 4a), one of 
two AAREs located in this region; this finding was consistent with previously published data16. In order to further 
confirm the involvement of ATF4 in elevation of FGF21 expression, we examined whether a dominant negative 
form of ATF4 (mATF4DN)23, which consisted of the C-terminal half containing the basic-leucine-zipper domain 
but lacking the N-terminal 200 amino acid residues, hindered the stimulating effect of WT ATF4 on FGF21 pro-
moter activity. Overexpression of mATF4DN significantly reduced the increase in WT ATF4-induced luciferase 
activity (Fig. 4b). Based on these findings, mice were infected with either a control Lac Z or mATF4DN-containing 
adenovirus to determine whether the increased hepatic FGF21 expression in response to β -conglycinin inges-
tion was hindered by overexpression of mATF4DN in vivo. β -conglycinin ingestion for 6 h after a 24 h fasting 
period significantly increased hepatic FGF21 expression and circulating FGF21 levels in control mice; in contrast 
overexpressed mAtf4dn significantly lowered the increase in hepatic FGF21 expression and serum FGF21 levels 
(e) Expression levels of FGF21 mRNA in the liver are normalized to cyclophilin mRNA levels and are 
shown as fold induction to expression levels in the casein group of WT mice. * P < 0.05 determined by two-
tailed Student’s t-test. (f‒k) Serum FGF21, glucose, insulin, triglyceride (TG), total cholesterol, and Igf-1 
concentrations. (l) Liver TG contents. (m) Liver total cholesterol contents. (n) Expression levels of ATF4 
target gene mRNA in the liver are normalized to cyclophilin mRNA levels and are shown as fold induction to 
expression levels in the casein group of WT mice. (o) Expression levels of mRNA related to lipid metabolism 
in the liver are normalized to cyclophilin mRNA levels and are shown as fold induction to expression levels in 
the casein group of WT mice. (p) Expression levels of mRNA related to bile acid metabolism in the ileum are 
normalized to β -actin mRNA levels and are shown as fold induction to expression levels in the casein group 
of WT mice. (q‒s) Expression levels of mRNA related to lipolysis in adipose tissues are normalized to 18S 
ribosomal RNA levels and are shown as fold induction to expression levels in the casein group of WT mice.
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induced by β -conglycinin ingestion. These results indicated that the activation of ATF4 contributed to an increase 
in FGF21 expression (Fig. 4c,d). Moreover, we examined whether increased ATF4 interacted with the AARE1 
sequence on the genomic DNA in response to β -conglycinin ingestion. Using liver genomic DNA, ChIP assays 
were performed with either an anti-ATF4 or anti-acetylated histone 3 antibody. Whereas ATF4 interactions with 
the distal unrelated region was not observed in either diet (Fig. 4e), β -conglycinin ingestion induced an increased 
interaction of ATF4, together with acetylated histone 3, to the region containing the AARE1 sequence in the 
FGF21 promoter region (Fig. 4f). When these results are combined, it is likely that ATF4 directly caused an 
increase in hepatic FGF21 gene expression and serum FGF21 serum levels after β -conglycinin ingestion.
Serum methionine levels control hepatic FGF21 gene expression. There is a difference in amino 
acid composition between milk protein casein and soy protein β -conglycinin. In particular, methionine content in 
β -conglycinin corresponds to approximately one-third of that found in casein. We, therefore, examined whether a 
newly designed diet composed of the mixture of amino acids included in β -conglycinin has the same postprandial 
effect as the whole β -conglycinin diet. Hepatic expression of ATF4 target genes, including FGF21, was greatly 
elevated after 6 h feeding in mice fed with only the β -conglycinin diet, whereas the amino acid mixture diet had 
no effect in a manner similar to the casein diet (Fig. 5a). These results indicate no causal relationship between the 
amino acid composition of β -conglycinin and the induced activation of the ATF4-FGF21 signaling axis. We next 
examined when FGF21 transcription started to increase after the beginning of β -conglycinin ingestion. In prelim-
inary experiments, we confirmed that mice ate at least 1.2 g of one of the diets within 1 h after 24 h fasting. Mice 
were fed with 1.2 g of one of the experimental diets for 1 h after 24 h fasting and were then sacrificed at 1, 2, 3, and 
6 h after the initiation of feeding. After 24 h fasting FGF21 expression was significantly increased, but at 1 or 2 h 
after feeding of any of the diets FGF21 expression levels were lower than those at 0-h level (Fig. 5b). This is most 
likely due to postprandial inactivation of PPARα that was significantly activated in response to the 24 h fasting. 
Figure 3. Beneficial effects of β-conglycinin in wild-type (WT) or PPARα-deficient (KO) mice. (a) Seven-
week old male WT and PPARα KO mice were acclimated to the casein high-fat diet for 7 days, and then fed 
with either the casein or β -conglycinin (β -con) diet for 4 weeks. Expression levels of FGF21 mRNA in the liver 
are normalized to cyclophilin mRNA levels and are shown as fold induction to expression levels in the casein 
group of WT mice. Serum FGF21 concentrations are shown. All data are expressed as means ± SD (n = 5–6).  
* * P < 0.01 determined by two-tailed Student’s t-test. (b) Body weight of mice. (c) Liver weight. (d) Epidydimal 
WAT weight. (e) Serum glucose concentrations. (f) Serum TG concentrations. (g) Serum total cholesterol 
concentrations.
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After 2 to 6 h, casein feeding further lowered FGF21 expression. In contrast, after 3 to 6 h, FGF21 expression was 
greatly increased in mice fed with the β -conglycinin diet, and at 6 h the expression level greatly exceeded the ini-
tial 0 time level. These results imply that liver recognized certain signals within 3 h after β -conglycinin ingestion.
Based on these results, we sought to determine free amino acid concentrations in portal blood serum at 1 h 
after feeding of either the casein or β -conglycinin diets. There were no significant differences in overall free amino 
acid concentrations between two groups (Fig. 5c). However, among essential amino acids we found decreased 
Figure 4. ATF4 stimulates hepatic FGF21 gene expression following β-conglycinin ingestion. (a) Mouse 
primary hepatocytes were transfected with 200 ng of one of reporter constructs, either pCMV 3xFLAG 
(mock) or pCMV 3xFLAG mATF4, and a β -galactosidase construct. After incubation for 48 h, luciferase and 
β -galactosidase activities were determined. Normalized luciferase values were determined by dividing the 
luciferase activity by the β -galactosidase activity. Relative activities are shown as fold induction to expression 
levels in the mFGF21-1133 bp together with pCMV 3xFLAG. (b) HEK293T cells were transfected as described 
in Fig. 4a. In the fourth group the cells were transfected with 350 ng of pCMV 3xFLAG mATF4 and 515 ng of 
pCMV 3xFLAG mATF4DN (a dominant negative form of mATF4). The structure of mATF4 and mATF4DN 
are depicted. Relative luciferase activities are shown as fold induction to expression levels in the mFGF21-
1133 bp together with pCMV 3xFLAG. One-way analysis of variance followed by the Bonferroni procedure 
was used. Different superscript letters denote statistical significance (P < 0.05). (c,d) Eight-week-old mice 
were injected through the tail vein with 1 × 109 pfu of adenovirus bearing either Lac Z or mATF4DN. After 
24 h, these mice were fasted for 24 h and then re-fed the β -con diet for 6 h. Hepatic FGF21 mRNA levels are 
normalized to 18S rRNA levels and are shown as fold induction to expression levels in the 24 h-fasted Lac Z 
group. Serum FGF21 concentrations are also shown. * * P < 0.01 determined by two-tailed Student’s t-test.  
(e,f) Livers obtained from mice fed for 3 h were processed for ChIP analyses. After immunoprecipitation with 
anti-ATF4, anti-acetyl-histone H3, or control IgG, real-time PCR analysis was performed with a primer set 
covering the region (− 6533 to − 6470) of the promoter in the mouse FGF21 gene, or the region covering the 
AARE sequence (as illustrated to the right side of Fig. 4e). The results were represented by fold enrichment 
relative to control IgG. The same results were obtained in two separate experiments. * P < 0.05 by two-tailed 
Student’s t-test. All data are expressed as means ± SD (n = 3).
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Figure 5. Methionine supplementation to the β-conglycinin diet negates the FGF21-stimulating effect. 
Five-week old mice were fasted for 24 h and then fed with the indicated high-fat diet. Using liver total RNA, 
RT-qPCR was performed and relative mRNA levels are normalized to cyclophilin mRNA levels. (a) Mice were 
fed with the diet for 6 h. Relative mRNA expression levels are shown as fold induction to expression levels 
of the indicated genes in the casein group. All data are expressed as means ± SD (n = 6). One-way analysis 
of variance followed by the Bonferroni procedure was used. Different superscript letters denote statistical 
significance (P < 0.05). (b) Mice fed with 1.2 g the diet and then sacrificed at the indicated time. Relative mRNA 
expression levels are shown as fold induction to expression levels at 0 (24-h fasted). All data (b–i) are expressed 
as means ± SD (n = 3). * P < 0.05 and * * P < 0.01 determined by two-tailed Student’s t-test. (c) Portal blood 
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concentrations of methionine, threonine, tryptophan, and valine in the β -conglycinin-fed mice. Several groups 
reported that treatment with a methionine-choline-deficient diet increased serum FGF21 levels despite induction 
of non-alcoholic steatohepatitis24,25. Based on these reports, we first examined whether methionine supplemen-
tation affected the increase in hepatic FGF21 expression and circulating FGF21 levels induced by β -conglycinin. 
Mice were fed with the methionine-supplemented diet, which was prepared by adding enough methionine to 
achieve a twofold increase in its dietary content (Supplementary Table 1), for 6 h after 24 h fasting. We found 
that the β -conglycinin effect was almost completely eliminated by this supplementation (Fig. 5d,e). In contrast, 
supplementation of one of three other amino acids had no effect on reducing the increased FGF21 expression 
and serum FGF21 levels caused by β -conglycinin consumption (Fig. 5f,g). These results imply that insufficient 
methionine availability, occurring only when mice were fed with β -conglycinin, resulted in the postprandial 
increase in hepatic FGF21 expression and serum FGF21 levels. If this was the case, the increased ATF4 protein 
should have been detected in the liver within 3 h. Western blot analysis revealed that at 2 h after β -conglycinin 
ingestion, hepatic ATF4 protein increased when compared with casein (Supplementary Fig. 1). However, 
an increase in ATF4 protein was also observed in the livers of mice fed either the amino acid mixture or the 
methionine-supplemented diet despite lack of elevation of FGF21 transcription caused by these diets. Moreover, 
an upstream regulatory factor for ATF4, phosphorylated eukaryotic initiation factor 2α (p-eIF2 α ), was not 
increased in response to feeding of any kind of diet. Taken together, it seems likely that ATF4 protein levels were 
not necessarily a determinant for promoting ATF4’s target gene expression in response to β -conglycinin inges-
tion. Furthermore, we repeatedly examined time-dependent changes in free methionine concentration in the por-
tal blood serum for 6 h after ingestion of several types of diets. Among the three diets, the β -conglycinin diet kept 
the methionine concentration at the lowest level during the 6 h period (Fig. 5h). In particular, a significant differ-
ence between the amino acid mixture and β -conglycinin diet was observed 1 h after feeding, suggesting that low-
ered serum methionine just after ingestion of β -conglycinin might result in a change in liver FGF21 expression.
To verify that decreased ATF4 interacted with the AARE1 sequence on the genomic DNA in response to 
ingestion of the methionine-supplemented or amino acid mixture diet, ChIP assays were performed with an 
anti-ATF4 antibody as shown in Fig. 4e. β -conglycinin ingestion again induced an increased interaction of ATF4 
to the region containing the AARE1 sequence in the FGF21 promoter region, whereas this increase was not 
observed after ingestion of other 3 diets (Fig. 5I,j).
FGF21 expression is increased in hepatocytes cultured in a medium with a lower methionine 
concentration. We hypothesized that the increase in hepatic FGF21 expression at 3 h after β -conglycinin 
ingestion might be triggered by a decrease in methionine concentration in the portal blood at 1 h. To assess this 
possibility, primary mouse hepatocytes were cultured in medium that contained free amino acid concentrations 
equal to those found in the portal blood at 1 h after ingestion of each diet (Supplementary Table 2). The total 
amino acid concentrations in Williams’ E medium (6.6 mM) are close to those in the postprandial portal blood 
at 1 h after ingestion of the casein, β -conglycinin, or amino acid mixture diet (4.7‒ 5.7 mM). Interestingly, the 
culture medium mimicking the amino acid concentrations in the portal blood of mice fed with the β -conglycinin 
diet induced an increase in FGF21 expression; in contrast, the culture media mimicking those for the amino acid 
mixture or methionine-supplemented diet underwent no changes in FGF21 expression when compared with the 
casein and Williams’ E medium (Fig. 6a). Incremental increases in methionine concentrations starting at 50 μ M, 
which corresponded to its concentration in portal blood of mice fed with the β -conglycinin diet, to 70 μ M, 
which corresponded to that for the amino acid mixture diet, significantly reduced FGF21 expression (Fig. 6b 
and Supplementary Table 2). In contrast, a decrease in methionine concentration in the β -conglycinin medium 
increased FGF21 expression in a dose-dependent manner. Furthermore, a decrease in methionine concentration 
in the amino acid mixture from 70 to 50 μ M had no effect on FGF21 expression even though the methionine 
concentration was reduced to the same level as that in the β -conglycinin medium; these results suggest that the 
methionine concentration itself is not a determinant for regulating FGF21 transcription. Trib3, another ATF4 tar-
get gene, showed a similar the dose-response pattern, but there were no significant differences (Fig. 6c). To exam-
ine molecular changes of the upstream factors involved in an increase in FGF21 expression, western blot analysis 
was performed for detecting phosphorylated eIF2α and ATF4 proteins. Both of them were increased in hepat-
ocytes cultured with the β -conglycinin medium independent of the methionine concentration when compared 
with the amino acid mixture medium (Fig. 6d). When these results are taken together, it appears that hepatocytes 
might function in sensing the methionine imbalance in the culture medium by accentuating FGF21 transcription 
via activation of ATF4. The same phenomenon may happen in the liver following ingestion of β -conglycinin.
serum was obtained at 1 h after feeding of the diet. (d,e) Mice were fed for 6 h. Relative mRNA expression levels 
are shown as fold induction to expression levels in the casein group. Serum FGF21 concentrations are also 
shown. Different superscript letters denote statistical significance (P < 0.05). (f,g) Mice were fed for 6 h. Relative 
mRNA expression levels are shown as fold induction to expression levels in the casein group. Serum FGF21 
concentrations are also shown. Different superscript letters denote statistical significance (P < 0.05). (h) Mice 
were fed with 1.2 g of the diet and then portal blood was collected at the indicated time. Serum methionine 
concentrations are shown. Different superscript letters denote statistical significance (P < 0.05). (i,j) ChIP 
analyses using anti-ATF4 or control IgG were performed as described in Fig. 4e,f. The results were represented 
by fold enrichment relative to control IgG in 4 different groups. The same results were obtained in two separate 
experiments.
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Discussion
The present study is the first to describe the molecular mechanism(s) by which ingestion of β -conglycinin, one 
of the soy proteins, has beneficial health effects. Notably, an unexpected finding was that the single ingestion of 
β -conglycinin induced increased hepatic FGF21 expression and postprandial FGF21 circulating serum levels; this 
was in sharp contrast with a control dietary protein (casein), which severely reduced both FGF21 expression and 
protein levels. It is usually accepted that the quality of dietary proteins can be evaluated after long-term feeding on 
the basis of the notion that their physiological effects are produced slowly over time. Nevertheless, DNA microar-
ray analyses performed in the present study enabled us to detect rapid changes in gene expression caused by a 
single ingestion of different types of dietary proteins. Importantly, even after long-term feeding of β -conglycinin 
(up to 9 weeks) we found that the increase in hepatic FGF21 expression and circulating FGF21 levels remained in 
a steady state, resulting in prevention of body weight gain, a decrease in blood glucose and liver triglyceride levels, 
and weight loss of adipose tissues (Fig. 6e).
Figure 6. Induced FGF21 gene expression in hepatocytes exposed to the media containing varying levels 
of methionine. Mouse primary hepatocytes were cultured with an amino acid-deficient medium for 1 h 
followed by the indicated medium for 2 h. Using their total hepatocyte RNA, RT-qPCR was performed and 
relative mRNA levels were normalized to 18 S ribosomal RNA levels. (a) Hepatocytes were cultured with the 
medium in which the amino acid concentrations were set up comparable with those in the portal blood serum 
of mice fed with one of the diets (the casein, β -con, or amino acid mixture) or Williams’ E medium. All data 
are expressed as means ± SD (n = 3). One-way analysis of variance followed by the Bonferroni procedure was 
used. Different superscript letters denote statistical significance (P < 0.05). (b,c) Hepatocytes were cultured with 
either the β -con or AA mix medium with various concentrations of methionine for 2 h. All data are expressed 
as means ± SD (n = 3). Different superscript letters denote statistical significance (P < 0.05). (d) Western 
blot analysis of the indicated protein expression in the cells cultured with the medium containing various 
concentrations of methionine for 2 h. β -actin serves as a loading control. The same results were obtained in 
three separate experiments. (e) Schematic model of the upregulation of hepatic FGF21 gene expression caused 
by β -conglycinin consumption.
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We also found that a single ingestion of β -conglycinin significantly induced an increase in gene expressions, 
including FGF21, which are regulated by the transcription factor, ATF4, and have been shown to become active 
in response to ER stress (Fig. 1b). Because no significant increases in ER stress marker genes were observed, 
it seems obvious that β -conglycinin ingestion activated ATF4 with no direct ER stress involvement. Our pres-
ent findings indicated that hepatic adenovirus-mediated expression of a dominant form of ATF4 reduced 
β -conglycinin-induced FGF21 expression and that a larger amount of ATF4 protein was recruited to the AARE 
motif localized in the FGF21 promoter region. We then wondered what was a determinant of ATF4 activation 
caused by the different dietary proteins. It is also known that dietary protein deficiency or an imbalance of essen-
tial amino acids increases ATF4 synthesis12,13,16,26. Mechanistically, the general control non-depressible 2 (GCN2) 
kinase acts as an amino acid sensor, leading to phsophorylation of the transcriptional initiation factor (eIF) 2α 
that suppresses general protein synthesis, but promotes an increase in translation of ATF4 mRNA. Several pre-
viously published papers showed a significant increase in ATF4 protein levels in cultured cells in response to an 
imbalance of essential amino acids, but only a slight change in its protein levels in vivo, with some exceptions, in 
response to either dietary protein deficiency or amino acid imbalance; these results are consistent with our pres-
ent results10,13,27,28. Because FGF21 expression significantly increased after a single ingestion of β -conglycinin in 
the current study, we predicted a sharp increase in ATF4 protein levels, but failed to detect it. At this time we do 
not know how ATF4 activity is induced. It is tempting to speculate that ATF4 protein modification such as phos-
phorylation or acetylation might occur and promote the transcriptional activation in response to β -conglycinin 
consumption29–31. Alternatively, we cannot rule out the possibility that other molecules capable of interacting with 
and modulating ATF4 might accelerate the transcription of ATF4 target genes32. Further studies will be required 
to determine the mechanism for liver ATF4 activation in response to β -conglycinin ingestion.
The finding that the amino acid mixture diet failed to reproduce the effect caused by β -conglycinin inges-
tion implies the possibility that certain peptides derived from digestion of β -conglycinin exerted a pharmaco-
logical action. However, this hypothesis was contradicted by the finding that the culture medium amino acid 
composition for primary hepatocytes played a critical role in increasing FGF21 expression. It is interesting 
that the transient methionine imbalance in portal blood occurred after β -conglycinin ingestion might result 
in an increase in hepatic FGF21 expression and circulating FGF21 levels. β -conglycinin is composed of three 
types of subunits, α , α ′ , and β  with all of the subunits sharing an identical N-terminal amino acid sequence 
(methionine-methionine-arginine). As a result, these six methionine residues among 11 residues contained in 
the three subunits led to disproportionate localization in their N-terminus. While β -conglycinin was digested 
and absorbed in the small intestine, this methionine dipeptide, if generated during the digestive process, might 
have a causal influence on the lower concentrations of free methionine in portal blood just after ingestion of 
β -conglycinin when compared with ingestion of the free amino acid mixture. Another unexpected finding in the 
current study was that primary mouse hepatocytes showed an increase in FGF21 expression when incubated with 
medium that contained identical amino acids to those observed in portal blood of mice fed with β -conglycinin 
when compared with those receiving casein. It is important to note that the low methionine concentration itself 
did not trigger increased FGF21 expression, based on the finding that the reduction of methionine concentrations 
in the culture medium to the same level as that for β -conglycinin failed to increase FGF21 expression (Fig. 6b). 
Nevertheless, the finding that incrementally reducing methionine concentration down to zero resulted in a fur-
ther increase in FGF21 expression in cultured hepatocytes (Fig. 6b) shows the importance of methionine; these 
findings are consistent with previously published findings12,26. It appears that a certain balance ratio between 
methionine and other amino acids might be critical for causing metabolic responses in hepatocytes. The same 
phenomenon was also shown in a report in which reduced alanine concentration in the culture medium of pri-
mary hepatocytes resulted in increased FGF21 expression13. In the current study, we observed no changes in por-
tal blood alanine concentrations when mice were fed either the casein or β -conglycinin diet (Fig. 5c). Meanwhile, 
β -conglycinin diet supplementation with one of essential amino acids, which were lowered in portal blood of 
mice fed with β -conglycinin, had no effect on increased hepatic FGF21 expression with the exception of methio-
nine supplementation (Fig. 5). These findings suggest the particularity of methionine. These results also indicate 
that the methionine imbalance in portal blood might directly or indirectly elicit the ATF4-FGF21 signaling axis 
activation in hepatocytes. Further studies are needed to elucidate the precise mechanism for sensing the methio-
nine imbalance by hepatocytes.
It should be noted that an increase in circulating FGF21 in response to 9-week β -conglycinin consump-
tion resulted in induction of lipolytic (Hsl and Atgl), Pgc-1α , and Adipoq expressions in adipose tissues in an 
FGF21-dependent manner (Fig. 2). In addition, we observed an increase in the Ucp-1 mRNA and Pgc-1α  protein 
levels in subcutaneous WAT of WT mouse fed with β -conglycinin, but not of FGF21-deficient mouse (Fig. 2r 
and Supplementary Fig. 2), suggesting that β -conglycinin might induce browning of subcutaneous WAT. These 
increases appear to contribute to a decrease in body weight gain and adipose tissue weights, and serum glucose 
levels. In a pilot experiment for 9 weeks, we observed increased energy expenditure in β -conglycinin-fed mice 
without any significant increase in locomotor activity (Supplementary Fig. 3). Although an increase in Ucp-1 
expression is believed to assist browning of WAT, recent papers demonstrated that the effects of FGF21 on body 
weight reduction and glucose homeostasis can occur in Ucp-1 knockout mice33,34. In contrast, some authors claim 
that FGF21 requires UCP1 to improve glucose clearance, likely involving increased UCP1-dependent thermogen-
esis35. Further experiments will be required to elucidate the link between FGF21 and Ucp-1 involved in beneficial 
effects caused by β -conglycinin.
Adiponectin, an adipokine predominantly secreted from adipocytes, regulates glucose and lipid metabo-
lism and improve insulin sensitivity. Because FGF21 enhances both expression and secretion of adiponectin 
in adipocytes36, elevation of circulating adiponectin levels on the basis of increased Adipoq gene expression in 
epididymal and subcutaneous WAT might be implicated in favorable effects caused by β -conglycinin consump-
tion. Contrary to our expectation, no significant difference in the adiponectin levels was observed in both WT 
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and FGF21-deficient mice (supplementary Fig. 4). It seems likely that the increase in Adipoq gene expression was 
not enough to induce increased its circulating levels.
Soy proteins have gained considerable attention for their role in improving risk factors for cardiovascular 
disease. In 1999, the FDA approved labeling for foods containing soy proteins as protective against coronary 
heart disease2. In contrast, the American Heart Association Nutrition Committee recently released a scientific 
advisory on soy protein, isoflavones, and cardiovascular health showing such favorable effects had not been con-
firmed37. Therefore, it is still controversial whether soy protein intake exhibits beneficial health effects in humans. 
Nevertheless, this study demonstrated that one of the soy protein components, β -conglycinin, produced a large 
positive metabolic impact in mice. So far several reports have shown that plasma FGF21 levels are not consist-
ently increased by fasting in humans unlike in rodents, clarifying a difference in controlled induction between 
species38–40. Moreover, because consuming a single protein in a normal eating routine is totally impractical in 
humans, it is hard to apply the current findings observed in rodents to humans. However, even in humans, it 
might theoretically be achievable to design dietary protein intake for exerting metabolic effects through activation 
of the ATF4-FGF21 pathway. This could be done by monitoring subtle alterations in portal blood amino acid lev-
els after meal ingestion and controlling them. Our current study sheds light on the postprandial impact of dietary 
protein intake on health and metabolism.
Methods
Plasmids. The mouse ATF4 (mATF4) construct was synthesized from total mouse hepatocyte RNA and 
cloned into the p3x FLAG-CMV-7 vector (Sigma-Aldrich Co.) using EcoRI and BamH1 sites. A mouse ATF4 
dominant negative (mATF4 DN) construct was synthesized from the mATF4 construct. For adenoviral exper-
iments, a mATF4 DN vector was subcloned into the corresponding sites of the Gateway pENTR1A vector 
(Invitrogen) and recombined into the destination vector pAd/CMV/V5-DEST (Invitrogen).
Mice and Diets. All experiments were performed with male mice. C57BL6 mice were obtained from CLEA 
Japan Inc. PPAR α − /− was obtained from Jackson laboratory. FGF21 − /− mice were kindly provided by Dr. N 
Ito41. All animal experiments were approved by the animal experiment committee of the University of Tokyo and 
the Nara Women’s University and performed in accordance with the relevant guidelines and regulations. Mice 
were housed in a 12-h light/dark cycle, with the dark cycle occurring between 9:00AM and 9:00PM. The mice 
were given free access to water and were initially fed a standard pellet diet (Labo MR Stock; Nosan Corporation 
Bio Department) during a 7-day acclimation period. For the fasting and re-feeding experiments, 24 h-fasted mice 
were fed each diet for 6 h. The fasted and re-fed mice were sacrificed at ZT1 and ZT7, respectively. In log-term 
feeding experiments anesthetized mice were sacrificed after 6 h-fasting (ZT7 in Fig. 2) or at ZT2 without fasting 
as shown in Fig. 3. The livers, intestines, and adipose tissues were rapidly excised, frozen in liquid nitrogen, and 
stored at − 80 °C until further processing. Blood samples were obtained, and the serum was separated and stored 
at − 80 °C until further processing. Diet composition is described in Supplementary Table 3.
Metabolite Measurements. Serum Glucose concentrations were measured using Glucose C2 test (Wako 
Chemicals Inc.). Total hepatic lipids were extracted from an approximately 200 mg piece of frozen liver tissue as 
previously described42. Serum triglyceride concentrations and triglyceride content of liver were measured using 
triglyceride E-test wako (Wako Chemicals Inc.). Serum cholesterol concentrations and cholesterol content of 
liver were measured using cholesterol E-test wako (Wako Chemicals Inc.). Serum insulin concentrations were 
measured using Lbis® Insulin-mouse ELISA Kit (T type) (SHIBAYAGI Co. Ltd.). Serum FGF21 concentrations 
were measured using Mouse/Rat FGF21 Quantikine ELISA kit (R&D Systems, Inc.). Serum Igf-1 concentrations 
were measured using Mouse/Rat IGF-1 Quantikine ELISA kit (R&D Systems, Inc.).
Amino acid analysis. Frozen tissue and serum samples were homogenized using a Precellys® 24 homog-
enizer (Bertin Technologies, Montigny le bretonneux, France) in a cold 80% methanol solution containing 
L-phenyl-d5-alanine as an internal standard and partitioned with chloroform to remove hydrophobic compo-
nents such as lipids. The water-soluble fractions were concentrated 10-fold using a centrifugal evaporator and 
applied for the amino acid analysis. The determinations of amino acids were performed according to the recently 
established method of LC-MS/MS43–45.
Mouse primary hepatocyte in culture. Mice primary hepatocytes were isolated from mouse liver by the 
two-step collagenase perfusion method. Briefly, Hank’s buffered salt solution (Sigma-Aldrich Co.) followed by 
collagenase (Wako) digestion medium was perfused through a cannula inserted from superior vena cava. After 
the viability was checked, 6 × 105 cells were plated in a collagen coated 6 well dish (Corning, USA) in Williams’ 
E Medium (Sigma-Aldrich Co.) supplemented with 10% fetal bovine serum, 10 nM dexamethasone, 2 mM glu-
tamine and 100 units/ml penicillin, 100 μ g/ml streptomycin and maintained at under 5% CO2 atmosphere.
Luciferase Assay. The FGF21 promoter construct − 1133/+ 130 was generated by PCR using mouse genomic 
DNA and the following oligonucleotides: − 1133 forward, 5′ -ATATGAGCTCCAGGAAACAACCCAGCTCTT-3′ ; 
+ 130 reverse, 5′ -ATATCTCGAG AGGCAGCTGGAATTGTGTTC-3′ . The PCR-amplified fragments were 
cloned into a luciferase reporter construct using Sac I and Xho I sites. To generate the AARE mutation fragment, 
− 1133/+ 130 FGF21 promoter constructs and the following oligonucleotides were used: forward 5′ -AGCGCAA 
CGGGAGGACAGCAGCTGAGCACAA-3′  ; reverse 5′ -TCCTAGTGCTTCTTTCACCAGACAG-3′  . 
All constructs were verified by DNA sequencing.
For transient transfection assays in Fig. 4a, mice primary hepatocytes were obtained from twelve-week old 
C57BL/6 male mice after collagenase perfusion. Mice primary hepatocytes were maintained in Williams’ E 
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medium containing 10% fetal bovine serum, 10 nM dexamethasone, 2 mM L-glutamine and 100 units/ml pen-
icillin, and 100 μ g/ml streptomycin and maintained under 5% CO2. Cells were plated in collagen coated 12-well 
plates at a density of 600,000 cells per well. For transient transfection assays in Fig. 4b, HEK293T cells were placed 
in 12-well plates at a density of 100,000 cells per well. These cells were maintained in DMEM supplemented with 
10% fetal bovine serum, containing 100 units/ml penicillin, and 100 μ g/ml streptomycin and maintained under 
5% CO2. After 6hr, cells were transfected using Lipofectamine 2000 (Invitrogen). Each well was transfected with 
FGF21 reporter gene, pCMV 3xFLAG or pCMV 3xFLAG mATF4, pCMV 3xFLAG mATF4 DN, and pCMV 
β -galactosidase. After 48hr transfection, luciferase and β -galactosidase assays were performed on Mini Lumat 
LB9506 (BERTHOLD). Luciferase activity was normalized to β -galactosidase activity.
Western blot analysis. Approximately 100 mg of liver was homogenized in 1 ml lysis buffer (50 mM Tris/
HCl, pH 8.0; 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, and 1% Triton X-100) using a Polytron homogenizer 
(Qiagen). After centrifugation at 16,000 × g for 5 min at 4 °C, the supernatant was collected and concentrations 
were measured using BCA kit (Thermo Fisher Scientific Inc). Western blotting was performed using antibodies 
against ATF4, p-eIf2α and total-eIF2α (Cell Signaling). Anti-β -actin (AC-15) was from Sigma. Anti-mouse-IgG 
and anti-rabbit-IgG were from Jackson. Immunoreactive proteins were visualized using ECL (GE Healthcare, 
Milwaukee, WI, USA) or Immobilon (Millipore) western blotting detection reagents. The signals on the mem-
brane were quantified with a LAS-3000 Luminoimager (Fujifilm, Tokyo, Japan).
In vivo Chromatin Immunoprecipitation. Frozen livers from mice fed with either casein or β -conglycinin 
were crushed into powder. DNA-protein cross-linking was performed by incubating powdered liver tissue 
(50 mg) with 1% formaldehyde in PBS containing 1 mM DTT and 1 mM PMSF for 10–15 min at room tem-
perature with gentle shaking. Cross-linking reactions were stopped by adding glycine to 0.125 M. Liver nuclei 
were isolated with a Dounce homogenizer in hypotonic solution followed by centrifugation at 4000 × g for 
1 min. Chromatin immunoprecipitation assays using liver nuclei were performed using a ChIP assay kit (Upstate 
Biotechnology) and anti-ATF4 antibody (5 μ g, Santa Cruz Biotechnology, Inc.) or control rabbit IgG (Millipore 
Corporation) or anti-acetyl-Histone H3 (Lys9 [Upstate Biotechnology]). Precipitated DNA was purified 
using a phenol-chloroform method and eluted in 50 μ l water. DNA was subjected to RT-qPCR analysis using 
the following oligonucleotides: FGF21 − 6533/− 6470 forward: 5′ -TCAGCATGCCTCCAAAGC-3′ , reverse: 
5′ -TCAGCCTTGAGGAAGAGTAGACA-3′ ; FGF21 AARE1 forward: 5′ -TGACTGCAGGAAACAACCCA-3′ , 
reverse: 5′ -AGCTGCTGTCCTCCCTGAT-3′ .
RT-qPCR Analysis. Primers were designed using Primer Express software (Applied Biosystems) based on 
GenBank sequence data. For RT-q-PCR reactions, mice cDNA was extracted by ISOGEN (Nippon Gene Inc.) and 
synthesized using high capacity cDNA Reverse Transcription kit (Applied Biosystems), and qPCR was performed 
using SYBR Green Master Mix (Roche). All reactions were performed on Step One Plus Real-Time PCR system 
(Applied Biosystems), and relative mRNA levels were calculated by the comparative threshold cycle method by 
using cyclophilin or 18S as the internal control. Sequences of primers used in RT-qPCR analysis are listed in 
Supplementary Table 4.
Generation and administration of recombinant adenoviruses. The recombinant adenoviruses were 
generated using the ViraPower™ Adenoviral Expression System (Invitrogen) in 293 A cells according to the man-
ufacturer’s instructions. The viral chromosome, which contains target proteins, was linearized by PacI and trans-
fected into 293 A to produce P1 virus. High-titer stocks of amplified recombinant adenoviruses were purified by 
two-step ultracentrifugation in cesium chloride gradient. After dialysis, viral titers were determined by the tissue 
culture infectious dose 50 method using 293 A cells. Viruses were diluted in PBS and administered through tail 
vein injection, using approximately 1 × 109 pfu/mice.
DNA microarray analysis. Transcriptional profiling of mouse liver was performed using the Mouse 
Genome 430 2.0 Array (Affymetrix, Inc., USA) and a 3′ IVT Express kit (Affymetrix, Inc., USA), according to the 
Affymetrix protocols (Affymetrix Genechip Fluidics Workstation). Briefly, 100 ng of total RNA was reverse tran-
scribed into cDNA using a poly (dT) oligonucleotide attached to a T7 promoter and converted to dsDNA. This 
was then used as a template for the synthesis of biotinylated aRNA by T7 RNA polymerase. Labeled aRNA was 
fragmented and hybridized to the array at 45 °C for 16 h. After hybridization, the array was washed and stained 
with streptavidin–phycoerythrin. Fluorescent signals were scanned using the Affymetrix GeneChip System.
Analysis of DNA microarray data. Affymetrix GeneChip Command Console software was used to reduce 
the array images to the intensity of each probe (CEL files). CEL files were quantified using the Factor Analysis 
for Distribution Free Weighted method (dfw) algorithm using the statistical language R. Differentially expressed 
genes were identified by applying the Rank Products method to the dfw quantified data. The annotation file for 
the Mouse Genome 430 2.0 Array was downloaded from the Affymetrix website. DAVID was used to detect over-
represented GO terms in each group of DEGs. We compared the DEGs with the Mouse Genome 430 2.0 Array 
background. The functional annotation chart, an integrated tool in DAVID, was applied to examine significantly 
overrepresented GO terms. A modified fisher exact P value (Expression Analysis Systematic Explorer score) of 
< 0.05 was accepted as significant.
Statistical Analysis. The data are expressed as mean ± SD. Statistical analysis was performed using the 
Ekuseru-Toukei Ver.2.0 (Social Survey Research Information). Comparisons between treatments were made by 
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a Student’s t test for two groups. One-way ANOVA followed by the Bonferroni procedure was used to compare 
more than two groups. Differences were considered significant at P < 0.05.
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